Nilsine Partners LLC Buys 238 Shares of Agilent Technologies, Inc. (NYSE:A)

Nilsine Partners LLC lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 2.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,006 shares of the medical research company’s stock after acquiring an additional 238 shares during the quarter. Nilsine Partners LLC’s holdings in Agilent Technologies were worth $1,344,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. McAdam LLC boosted its stake in shares of Agilent Technologies by 3.1% in the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares during the period. Brown Brothers Harriman & Co. boosted its stake in Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after purchasing an additional 77 shares during the period. Global Retirement Partners LLC grew its holdings in Agilent Technologies by 3.2% during the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock valued at $382,000 after buying an additional 79 shares in the last quarter. Rovin Capital UT ADV raised its position in shares of Agilent Technologies by 1.6% during the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after buying an additional 81 shares during the last quarter. Finally, Marshall Financial Group LLC lifted its holdings in shares of Agilent Technologies by 1.0% in the third quarter. Marshall Financial Group LLC now owns 8,243 shares of the medical research company’s stock worth $1,224,000 after buying an additional 82 shares in the last quarter.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $150.35 on Wednesday. Agilent Technologies, Inc. has a 12-month low of $124.16 and a 12-month high of $155.35. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $138.91 and a 200-day moving average price of $138.37. The firm has a market capitalization of $42.94 billion, a PE ratio of 34.02, a price-to-earnings-growth ratio of 4.12 and a beta of 1.06.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The business had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were paid a $0.248 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $0.99 dividend on an annualized basis and a yield of 0.66%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.40%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on A shares. Barclays cut their target price on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research note on Wednesday, November 27th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Wells Fargo & Company dropped their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. JPMorgan Chase & Co. reduced their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Finally, Sanford C. Bernstein lowered their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $143.62.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.